Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies

The advent of new obesity medications has transformed the care of the disease of obesity, reframing weight loss from an aspirational goal to a realistic therapeutic outcome. Disease modifying agents capable of controlling obesity with meaningful metabolic improvement have reshaped expectations for both clinicians and patients (1). However, as efficacy has advanced, tolerability has emerged as a central clinical challenge for long term compliance with these medications (2). Adverse effects: particularly gastrointestinal can limit the benefits of treatment, especially if treatment is discontinued (3). The clinical challenge is therefore to manage treatment burden in a way that prevents early discontinuation, because only sustained, long-term therapy can optimise metabolic, cardiovascular, and weight related benefits.Nausea and vomiting remain among the most frequent and disruptive adverse effects across Glucagon-like peptide (GLP-1)-based therapies (4). As the treatment landscape expands beyond GLP-1 only receptor agonists to include multi-agonist and oral agents, these symptoms continue to influence initiation, titration, , and persistence with therapy. Although gastrointestinal intolerance is often most pronounced during early dose escalation and may attenuate over time, substantial inter-individual variability persists, highlighting the gap between therapeutic efficacy and real-world acceptability (4).In this opinion article, we examine the mechanisms underlying nausea and vomiting in semaglutide, CagriSema, survodutide, tirzepatide, retatrutide, and orforglipron and situate them within obesity clinical practice (5)(6)(7)(8)(9)(10)(11)(12)(13)(14). Importantly, approximately 60-70% of patients can titrate to the full therapeutic dose and with minimal difficulty, experiencing little to no gastrointestinal adverse effects (8,11,14). However, the remaining 30-40% may struggle during the escalation phase, developing nausea, vomiting, or treatment-limiting intolerance (14). Thus, the existing titration schedules used in phase 3 clinical trials can be appropriate for the majority of patients, but more attention should be given to the minority of patients who do have substantial side effects. The challenge remains that prior to treatment initiation it remains virtually impossible to predict who will have side effects (3).We also propose practical strategies to mitigate gastrointestinal intolerance; particularly nausea and vomiting to support treatment continuity. The goal is to help patients remain on an effective therapy long enough to achieve sustained metabolic and cardiovascular benefit without unnecessary interruption. A helpful framework comes from insulin titration. With insulin, mild hypoglycaemia signals that dose escalation is progressing faster than the body can handle, prompting a pause or small adjustment. Severe hypoglycaemia indicates clearly that the insulin dose is too high requiring a more substantial correction. Titration schedules in phase 3 trials of long acting insulin analogues incorporated individualization to allow the clinician to increase the dose to achieve optimal benefit without causing hypoglycaemia (15). Similarly, with GLP-1 therapy, nausea functions like mild hypoglycaemia, which can be seen as an early warning to slow or temporarily pause titration. Vomiting parallels severe hypoglycaemia, indicating intolerance significant enough to stepping back to the last well tolerated level. This parallel reinforces that symptoms are not failure, but physiological feedback guiding safer, more individualized titration.The oral GLP-1 based agents approved for obesity treatment deliver substantial weight loss. Oral semaglutide 25-50 mg produces the largest average reduction, followed by orforglipron closely behind (5)(6)(7). The main practical difference lies in how patients take them: both semaglutide tablets require a fasting routine and specific timing around meals, while orforglipron can be taken more flexibly, which may improve convenience. However, oral semaglutide remains an acylated peptide with very low bioavailability (